The Rare Disease Desert Symposium will officially kick off at 1pm MST on Monday, February 26th, with registration at Icagen-T in Tucson, AZ. Attendees coming from the east or west coast of the US will be able to travel that morning, as there are several early flight options to both Tucson and Phoenix. Alternatively, attendees can arrive Sunday, February 25th, and spend Monday morning at Icagen-T for a guided site tour.
Please note the following agenda is in Mountain Standard Time (MST).
Day 1: Monday, February 26, 2018
Chris Mathes, Ph.D., MBA, Chief Commercial Officer, Icagen
Ken Wertman, Ph.D., SVP and Site Director, Icagen
Muscular Dystrophies 1: DMD
Paul August, Ph.D., VP, Biology, Icagen (Chair)
|3:00pm||Prof. Louis Kunkel
Professor of Pediatrics, Dept. of Genetics, Harvard University
"Identification of genetic modifiers of muscular dystrophy"
|3:30pm||Coffee & Networking Break|
|4:00pm||Prof. Eric Hoffman
Chairman, Department of Integrative Systems Biology, George Washington University
"Context of use and fit for purpose: Integration of pharmacodynamic biomarkers into the vamorolone clinical program"
|4:30pm||Prof. Andy Berglund
Department of Biochemistry and Molecular Biology, Center for NeuroGenetics, University of Florida
"Exploiting a chink in the armor of myotonic dystrophy to develop novel therapeutic compounds"
|5:00pm||Prof. Rita Perlingeiro
Cardiovascular Division, University of Minnesota; Lillehei Professor in Stem Cell and Regenerative Cardiovascular Medicine, Lillehei Heart Institute
"Pluripotent Stem Cells in DMD: Potential for Cell Therapy, Disease Modelling, and Drug Discovery"
|5:30pm||Dr. Jane Larkindale
Executive Director, Duchenne Regulatory Science Consortium (D-RSC), Critical Path Institute
"Data Sharing and Development of Drug Development Tools through the Duchenne Regulatory Science Consortium (D-RSC) to Accelerate Drug Development"
Doug Krafte, Ph.D., Chief Scientific Officer, Icagen
Hilton Tucson El Conquistador
Day 2: Tuesday, February 27, 2018
|8:00am||Continental Breakfast & Registration|
Emily Kamer-Golinkoff, Co-Founder of Emily's Entourage
Muscular Dystrophies 2: FSHD & EDMD
Prof. Michael Kyba (Chair)
|9:15am||Dr. Angela Cacace
Vice President, Biology, Fulcrum Therapeutics
"Balancing Gene Regulation in an Era of Precision Medicine: FXS and FSHD"
|9:45am||Prof. Michael Kyba
Lillehei Endowed Scholar, Carrie Ramey / CCRF Endowed Professor in Pediatric Cancer Research, Department of Pediatrics
"FSHD: Disease models and prospects for therapy"
|10:15am||Dr. Sue Shackleton
Dept. of Molecular and Cell Biology, University of Leicester, UK
"The missing LINC between the nuclear envelope and rare myopathies"
|10:45am||Coffee & Networking Break|
Other Rare Diseases
|11:00am||Dr. Brady Maher
Lead Investigator at the Lieber Institute for Brain Development, Johns Hopkins University
"Identification and validation of SCN10a/Nav1.8 as a therapeutic target for Pitt Hopkins Syndrome"
|11:30am||Dr. Robert Ring
|12:00am||Dr. Christopher VanDeusen
President and co-Founder, Omdana Therapeutics
"Understanding the Relaxin Pathway and its impact on Pulmonary Hypertension"
|12:30pm||Lunch Break & Posters|
Prof. Justin Ichida (Chair)
|2:00pm||Prof. Justin Ichida
Stem Cell & Regenerative Medicine, Keck School of Medicine, University of Southern California
"Identification of Therapeutic Targets for ALS and FTD Using Phenotypic Screens on Patient-derived Models"
|2:30pm||Prof. Aaron Gitler
Genetics, Stanford University
"Expanding mechanisms and therapeutic targets for ALS"
|3:00pm||Prof. Don Cleveland
Chair, Department of Cellular and Molecular Medicine; Distinguished Professor of Cellular and Molecular Medicine, Medicine, and Neurosciences Member, Ludwig Institute for Cancer Research
"Gene silencing therapy for neurodegenerative disease"
Martin Mense, Ph.D. (Chair)
|4:00pm||Prof. Robert Bridges
Physiology and Biophysics, Chicago Medical School
"Advancing the search for epithelial ion channel modulators"
|4:30pm||Dr. Martin Mense
Vice President for Drug Discovery, Cystic Fibrosis Foundation Therapeutics
"Beyond CFTR F508del – Research at the CFFT Lab"
|5:00pm||Dr. Tim Young
Research Fellow at Vertex
|5:30pm||Close of Symposium and Closing Remarks
Richie Cunningham, CEO, Icagen
|6:00pm||Reception on deck at Icagen-T for those remaining|